# Biotangents

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biotangents

- Industry: Medical Devices & Equipment
- Headquarters: UK
- Website: www.biotangents.co.uk
- Total disclosed funding: $4.7M
- Latest round: Seed (Aug 1, 2021)
- Investors on record: 2

## About

Based in the UK, founded in 2015 by Andy Hall-Ponselè and Lina Gasiunaite, Biotangents Limited operates as a diagnostic technology firm that offers lab-based AmpliSpec BVD and Mastitis products. In May 2022, Biotangents Limited raised GBP 1.6 million in venture debt financing from Innovate UK. As of 2023, the company is led by its CEO, Fiona Marshall.

Biotangents provides disease diagnosis solutions for the veterinary and farming sectors and also provides diagnostic tests for infectious diseases in animals. The company’s product line includes Moduleic Sensing, which is a diagnostic technology platform that uses isothermal amplification technology to develop diagnostic tests that help detect infectious diseases, mainly bovine viral diarrhea (BVD) and mastitis in livestock animals; an AmpliSpec LAB, a diagnostic laboratory that offers in vitro diagnostic solutions; AmpliSpec VET tests; AmpliSpec LAB Mastitis, which is a molecular diagnostic tool for farmers, veterinarians, and laboratories to help diagnose and manage bovine mastitis; and many more.

## Funding rounds

- Seed, Aug 1, 2021, $2M — Kelvin Capital
- Series A, Mar 29, 2019, $2M — Kelvin Capital, Scottish Enterprise
- Seed, Mar 28, 2018, $0.6M — Kelvin Capital, Scottish Enterprise
- Seed, Dec 21, 2017, $0.1M — Kelvin Capital

## Investors

- Kelvin Capital (https://capitalatlas.ai/funds/kelvin-capital) — Seed, Series A
- Scottish Enterprise (https://capitalatlas.ai/funds/scottish-enterprise) — Seed, Series A